2023 Co-Chairs
Christine Bellon
Chief Legal Officer
Beam Therapeutics, Inc.
Sharick Naqi
Director & Senior Counsel
Global IP Lead – Gene Therapies
Novartis Gene Therapies
In-House Perspectives from
Todd Spalding
SVP, Deputy General Counsel
Alexion, AstraZeneca Rare Disease
Rana Sawaya
Senior Patent Counsel Celle & Gene Patent Lead
BioNTech SE
Ken Nesmith
CBO, Oncology
Lunit
Kelly Morgan
VP, Head of IP and Legal
Arbor Biotechnologies, Inc.
GOVERNMENT SPEAKERS INCLUDE
Julia Tierney
Chief of Staff
U.S. Food and Drug Administration (FDA)
Anne Gussow
Supervisory Patent Examiner, Quality Assurance Specialist
USPTO
Karlheinz Skowronek
Supervisory Patent Examiner, Bioinformatics
USPTO
Julie Wu
Supervisory Patent Examiner, Immunotherapy and Recombinant Antibodies
USPTO
Be part of the discussions that will shape and transform the future of therapeutics
mRNA, CRISPR, CAR T – all acronyms for emerging and novel therapeutics that are changing modern medicine as we know it. However, the complexities concerning ownership, funding, and tech strategies for these next generation therapeutic modalities and gene therapies are the greatest barriers to commercialization.
ACI has created The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies to provide you with solutions to some of the greatest challenges impeding market access for these products.
We are pleased to announce that representatives from the USPTO and FDA, as well as, distinguished in-house and outside counsel, will present at this groundbreaking event to discuss IP and regulatory initiatives that are essential to the proliferation of these therapeutics.
Critical sessions will cover:
- What Every Life Sciences Business Executive and Counsel Need to Know about the mRNA and CRISPR Patent War
- Assessing Competitors, Mapping Opportunities, and Mastering the IP Due Diligence Process
- Best practices for Securing Financing and Capital Formation
- Leveraging the Power of AI, ML, Automation and Data for the Development of Better Medicines
Obtain Industry Acumen from
- Akouos
- Alexion, AstraZeneca Rare Disease
- Arbor Biotechnologies, Inc.
- Beam Therapeutics, Inc.
- BioNTech SE
- Ferring Pharmaceuticals
- Lunit
- Novartis Gene Therapies
- Nutcracker Therapeutics
CLE Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Concerned About Traveling?
Check out our WORRY-FREE GUARANTEE
Register at the preferred early rate with our worry free cancellation guarantee.
Learn MoreRelated Conferences
